• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    The impact of atherosclerotic cardiovascular disease, dyslipidaemia and lipid lowering therapy on Coronavirus disease 2019 outcomes: an examination of the available evidence

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Adam, Safwaan
    Ho, Jan Hoong
    Bashir, B.
    Iqbal, Z.
    Ferdousi, M.
    Syed, A. A
    Soran, H.
    Affiliation
    The University of Manchester, Faculty of Biology, Medicine and Health Department of Endocrinology
    Issue Date
    2021
    
    Metadata
    Show full item record
    Abstract
    Purpose of review: Coronavirus Disease 2019 (COVID19) has caused significant global morbidity and mortality, especially in persons with underlying cardiovascular disease. There have been concerns that lipid-lowering therapy (LLT) increases angiotensin-converting enzyme 2 levels. Conversely, pleiotropic effects of statins can theoretically protect against severe COVID19 infection, supporting evidence from other respiratory illnesses in which statin use probably confers benefit. Recent findings: There is an abundance of studies that show that statins are safe and potentially protect against severe COVID19 infection (critical illness and death), even when adjustment for potential confounders is undertaken. However, the evidence is limited to retrospective cohorts. The benefit for patients with diabetes is less clear. There is a paucity of evidence for other LLT agents. Available clinical guidelines recommend the ongoing use of LLT in patients with COVID19 (unless specifically contra-indicated) and the data from available studies support these. Summary: In patients with COVID19 infection, LLT should be continued. However, the current findings need substantiating in larger prospective clinical studies with specific examination of the possible mechanisms by which LLT confers benefit from COVID19.
    Citation
    Adam S, Ho JH, Bashir B, Iqbal Z, Ferdousi M, Syed AA, et al. The impact of atherosclerotic cardiovascular disease, dyslipidaemia and lipid lowering therapy on Coronavirus disease 2019 outcomes: an examination of the available evidence. Current Opinion in Lipidology . 2021 Jun 9;32(4):231–43.
    Journal
    Current Opinion in Lipidology
    URI
    http://hdl.handle.net/10541/624252
    DOI
    10.1097/mol.0000000000000763
    PubMed ID
    34116544
    Additional Links
    https://dx.doi.org/10.1097/mol.0000000000000763
    Type
    Other
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1097/mol.0000000000000763
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Dyslipidaemia in patients with chronic kidney disease - a neglected cardiovascular risk factor.
    • Authors: Essop MR, Seedat F, Raal FJ
    • Issue date: 2023 Nov 6
    • The effect of the intensity of lipid-lowering medications on the LDL cholesterol treatment goals of Asian patients with dyslipidaemia in primary care.
    • Authors: Tan NC, Goh CC, Goh SC, Koh YL, Koh KH
    • Issue date: 2016 Dec
    • Use of lipid-lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2-year results from Getting to an imprOved Understanding of Low-Density lipoprotein cholesterol and dyslipidemia management (GOULD).
    • Authors: Shaik A, Kosiborod M, de Lemos JA, Gao Q, Mues KE, Alam S, Bhatt DL, Cannon CP, Ballantyne CM, Rosenson RS, GOULD Investigators
    • Issue date: 2022 Dec
    • Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    • Authors: Tenenbaum A, Fisman EZ, Motro M, Adler Y
    • Issue date: 2008
    • A Clinical Guide to Combination Lipid-Lowering Therapy.
    • Authors: Russell C, Sheth S, Jacoby D
    • Issue date: 2018 Mar 7
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.